Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O75223
UPID:
GGCT_HUMAN
Alternative names:
Cytochrome c-releasing factor 21
Alternative UPACC:
O75223; B2RDN0; B8ZZN4; B8ZZR8; Q9BS37
Background:
Gamma-glutamylcyclotransferase, also known as Cytochrome c-releasing factor 21, plays a pivotal role in glutathione homeostasis by catalyzing the formation of 5-oxoproline from gamma-glutamyl dipeptides. Its ability to induce the release of cytochrome c from mitochondria underscores its importance in apoptosis regulation.
Therapeutic significance:
Understanding the role of Gamma-glutamylcyclotransferase could open doors to potential therapeutic strategies. Its involvement in glutathione homeostasis and apoptosis makes it a compelling target for drug discovery efforts aimed at treating diseases where these processes are dysregulated.